Eaton Vance Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $143M | Sell |
1,347,820
-121,797
| -8% | -$12.9M | 0.21% | 99 |
|
|
2022
Q2 | $143M | Buy |
1,469,617
+13,569
| +0.9% | +$1.32M | 0.2% | 107 |
|
|
2022
Q1 | $137M | Sell |
1,456,048
-390,867
| -21% | -$36.6M | 0.16% | 138 |
|
|
2021
Q4 | $157M | Sell |
1,846,915
-38,991
| -2% | -$3.32M | 0.19% | 109 |
|
|
2021
Q3 | $181M | Buy |
1,885,906
+652,772
| +53% | +$62.7M | 0.25% | 84 |
|
|
2021
Q2 | $120M | Buy |
1,233,134
+416,718
| +51% | +$40.6M | 0.16% | 132 |
|
|
2021
Q1 | $79.4M | Buy |
816,416
+287,927
| +54% | +$28M | 0.12% | 182 |
|
|
2020
Q4 | $50.7M | Buy |
528,489
+399,834
| +311% | +$38.3M | 0.08% | 236 |
|
|
2020
Q3 | $12.4M | Hold |
128,655
| – | – | 0.02% | 442 |
|
|
2020
Q2 | $15.7M | Hold |
128,655
| – | – | 0.03% | 370 |
|
|
2020
Q1 | $11.1M | Buy |
128,655
+10,634
| +9% | +$920K | 0.03% | 392 |
|
|
2019
Q4 | $12.7M | Sell |
118,021
-16,007
| -12% | -$1.72M | 0.02% | 414 |
|
|
2019
Q3 | $12.1M | Hold |
134,028
| – | – | 0.03% | 406 |
|
|
2019
Q2 | $11.3M | Sell |
134,028
-28,973
| -18% | -$2.45M | 0.02% | 407 |
|
|
2019
Q1 | $14.4M | Buy |
163,001
+33,567
| +26% | +$2.96M | 0.03% | 344 |
|
|
2018
Q4 | $9.24M | Buy |
129,434
+22,280
| +21% | +$1.59M | 0.02% | 380 |
|
|
2018
Q3 | $13.2M | Buy |
107,154
+27,331
| +34% | +$3.36M | 0.03% | 362 |
|
|
2018
Q2 | $7.84M | Sell |
79,823
-29,125
| -27% | -$2.86M | 0.02% | 437 |
|
|
2018
Q1 | $9.04M | Buy |
108,948
+88,948
| +445% | +$7.38M | 0.01% | 532 |
|
|
2017
Q4 | $1.55M | Buy |
+20,000
| New | +$1.55M | ﹤0.01% | 752 |
|